Novo Ventures is ready for steady deployment of funds amid IPO lull
Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.
Tag Archive for: Optimum
How Early-stage VCs are Adjusting in a Bear Market
As part of a panel session, hosted by Stephen Hansen, at the Anglonordic Life Science conference on 5 May, Optimum’s clients explored the latest dynamics of syndicate building for early-stage VCs.
Destiny Pharma appoints Dr Yuri Martina as CMO
Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer Brighton, United Kingdom – 3rd May 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO). Read more
Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics
Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch Proceeds will be used to develop next-generation T-cell receptor-based therapies for cancer treatment TCR therapy pioneer and industry veteran Dr Bent Jakobsen appointed as Chairman of the Board Basel, Switzerland, May 3, 2022. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel […]
In Vivo’s 30 ‘Rising Leaders’ Announced
The 3rd annual listing of In Vivo’s ‘Rising Leaders’ has landed! Optimum is thrilled to see our brilliant clients from M Ventures, INKEF Capital, BioQube, Healthcap and Octarine recognised alongside other leading entrepreneurs and innovators in healthcare, from all across the globe. The 30 people spotlighted have been recognized for bringing something new to the […]
